Introduction:
The prostanoids mediate a diversity of cellular processes under various physiologic and patho-physiologic settings [1, 2] . Derived mainly from arachidonic acid liberated from membrane phospholipids, through the actions of phospholipase A 2 , the 5 primary prostanoids include the prostaglandins (PGs), PGD 2 , PGE 2 , PGF 2α , PGI 2 (prostacylin) and the thromboxanes (TXs) including TXA 2 . PGG/H synthase 1 and 2, also known as cyclooxygenase 1 and 2 (COX1 and 2), catalyse the first enzymatic step in the conversion of arachidonic acid into PGG 2 , and onward into the common precursor PGH 2 , and it is this enzymatic step that is the target for inhibition by aspirin and other non steroidal anti-inflammatory inhibitory drugs (NSAIDs) and by the more recently developed COX1/2 selective inhibitors [1, [3] [4] [5] . PGH 2 is thereafter converted to the various prostanoids, in a cell and tissue specific manner, through the actions of their respective PG and TXA synthases [1] .
The prostanoids TXA 2 and PGI 2 (prostacyclin) play key yet opposing roles in the local control of vascular hemostasis [1, 6, 7] . TXA 2 was first described by Hamberg et al., in 1975 as an unstable platelet-aggregating factor with a novel bicyclic oxane ring and with a half-life of 30 s [8] . Within the vascular system, it is a potent stimulator of platelet aggregation and causes vasoconstriction; on the other hand, PGI 2 inhibits platelet aggregation and causes vasodilation [1, 6] . TXA 2 also stimulates PGI 2 release from endothelial cells [9] and, under certain clinical or pathological situations, mediates mitogenic and / or hypertrophic responses in vascular smooth muscle (VSM) [10, 11] . Perturbations in the levels of these two prostanoids, their synthases or their receptors have been implicated in a number of cardiovascular disorders including myocardial infarction, unstable angina, atherosclerosis, pregnancy-induced hypertension and ischemic heart disease [12] [13] [14] [15] [16] . Moreover, a number of genetic bleeding disorders have been described in humans where the individuals' platelets were unresponsive to TXA 2 [17] . Both TXA 2 and PGI 2 signal through their signature receptors, each members of the G protein coupled receptor (GPCR) superfamily [1, 2, 6, 7] . TXA 2 interacts with the TXA 2 receptor, also termed TP or T Prostanoid receptor, whereas PGI 2 interacts with the PGI 2 receptor, also termed IP or I Prostanoid receptor [18, 19] . Greater understanding of the molecular mechanisms governing the interaction between TXA 2 , PGI 2 and their receptors as well as a greater understanding of the interplay between their signal transduction pathways should lead to a greater appreciation of their involvement in vascular hemostasis under normal and patho-physiologic conditions. In this review, I will describe some recent advances in the field of TXA 2 /TP signalling and how they may impinge on our current understanding of prostanoid-regulated vascular hemostasis.
Expression of the TP isoforms:
A cDNA for the human TXA 2 receptor (TP) was originally cloned from placenta and the platelet like MEG-01 cell line [20] and since then cDNAs for TPs from a number of species have been cloned and characterised [21] [22] [23] [24] [25] . All TPs are predicted to share the seven α-helical transmembrane domain arrangement typical of other members of the GPCR superfamily [26] .
Despite earlier, extensive pharmacological and biochemical evidence suggesting the existence of inter and intra-species variants of TPs [27] [28] [29] [30] , genomic cloning confirmed the existence of a single TP gene which, in humans, is located on chromosome 19p13.3 [31] . Despite this, Raychowdhury et al., [32] later isolated a cDNA encoding a second form (isoform) of the TP from a human umbilical vein endothelial cell (HUVEC) cDNA library. Thus, in humans, there are 2 receptors for TXA 2 , termed TPα and TPβ [20, 31, 32] , where the TP originally cloned from platelet/placenta is commonly referred to as the TPα isoform and that from HUVECs referred to as the TPβ isoform. The TP isoforms are identical for their N-terminal 328 amino acid (aa) residues but differ exclusively in their carboxyl terminal cytoplasmic (C-tail) domains such that TPα has 15 amino acid residues within its unique C-tail sequence and TPβ has 79 residues within its C-tail sequence [20, 31, 32 ; Figure 1 ]. TPα and TPβ are encoded by the single TP gene, on chromosome 19p13.3 [31] , and arise by a novel differential splicing mechanism within Exon 3 whereby nucleotides 984 -1642 of the TPα mRNA behave as an Intron (Intron 2b) within the TPβ mRNA [20, 31, 32 ; Figure 1 ]. Reverse transcriptase polymerase chain reaction (RT PCR) experiments indicated that HUVECs express only TPβ [32] whereas human platelets were reported to express both TPα and TPβ isoforms [33] . The physiologic significance for the existence of 2 receptors for TXA 2 in humans, but not in other species thus far investigated [21] [22] [23] [24] [25] , is currently unknown but is an area of extensive research interest within my laboratory.
Thus, as an essential prerequisite into studies investigating the potential differential roles of the TPα and TPβ receptors, we initially investigated the expression and tissue distribution of the TP isoforms in cells and tissues of relevance to TXA 2 biology [34] . Whereas Northern blot analyses had previously confirmed the existence of TP mRNA in human MEG-01 cells, placenta and lung [20] , in human erythroleukemic (HEL) cells [35] [36] [37] , these studies did not discriminate between the expression of the TPα and TPβ isoforms. Thus, through a series of studies involving RT PCR, Southern blot and phosphorimage analyses and radioligand binding studies, we found that both TPα and TPβ were expressed in the 17 tissues and cell types studied, with rare exceptions [34] . Whereas the levels of TPα expression predominated and were similar in most of the cell /tissue types examined, extensive differences in the levels of TPβ expression were observed [34] . Thus, the relative expression of TPα / TPβ varied considerably due to extensive differences in the level of TPβ expression. Most strikingly, contrary to previous reports that HUVECs expressed only TPβ mRNA sequences [32] , our studies established that primary HUVECs expressed only low levels of TPβ but rather expressed 6-fold greater levels of TPα than TPβ mRNA [34] .
Expression of TP mRNAs in the various cell / tissue types examined correlated with protein expression, as assessed by radioligand binding using the selective TP antagonist [ 3 H]SQ29,548 [34] . Additional immunofluorescence studies, employing TP isoform specific antibodies directed to peptide sequences within the unique C-tail domains of TPα and TPβ, also confirmed the expression and cellular localisation of the TP receptors [38, 39] . Taken together, these studies investigating the expression and tissue distribution of the TPα and TPβ receptors indicate that they are subject to differential expression and regulation [34] . The molecular basis of this differential expression is currently unknown and whether it is solely attributable to cell/tissue specific differential splicing, giving rise to the TPα and TPβ mRNA's, or whether it may be due to other factors, such as alternative promoter utilisation [31, 40, 41] , remains to explored at the molecular level. Moreover, whether there is any correlation between the differential levels of TPα versus TPβ expression and TXA 2 associated disease status is currently unknown but, given that the molecular tools are now in place, this important and interesting question could be readily addressed.
TP isoform signalling:
As previously stated, the TP isoforms are identical for their N-terminal 328 aa residues but differ exclusively in their C-tail domains [20,32; Figure 1 ]. From structure/ function relationship studies carried out with other prototypical GPCRs, including the β 2 adrenergic receptor [26, 42, 43] , it is widely accepted that while the C-tail domains of GPCRs do not appreciably influence ligand binding, they can indeed play an essential role in determining the specificity and / or efficiency of receptor: heterotrimeric G protein coupling and effector regulation, and may also play an essential role in GPCR desensitization following ligand activation [26, 42, 43] . The major mode of signalling of TXA 2 and its receptor is activation of the β isozymes of phospholipase (PL) C leading to phosphatidylinositol (PI) turnover and release of calcium from intracellular stores ([Ca 2+ ] i ) [44] . Using a variety of approaches involving either reconstitution studies [45, 46] , co-purification or co-immunoprecipitations [47] [48] [49] , photo-cross linking studies with GTP analogs [50] or co-expression studies [51] [52] [53] [54] , various investigators have proposed that the platelet TPs might couple to the G proteins G q , G 12 , G 13 , G 16 and G i2 . In studies involving the cloned receptor, co-expression of the TPα isoform with either G q or G 13 increased its affinity for I-BOP in COS-7 cells [51] . It has also been demonstrated that TPα can functionally couple to both G q and G 11 following stimulation with the selective TXA 2 mimetic, U46619 to mobilize [Ca 2+ ] i [54, 55] . Recently, Hirata et al., [33] demonstrated that the TP isoforms over-expressed in Chinese hamster ovary cells oppositely regulate adenylyl cyclase activity with TPα activating adenylyl cyclase, through Gα s and TPβ inhibiting it, through Gα i [33] , suggesting a possible role for the C-tail of TP in determining G protein specificity. Moreover, TPα, but not TPβ, mediates agonist activation of G h , the novel high molecular weight G protein [56] [57] [58] [59] , leading to PLC activation and PI turnover [60] .
Whereas many of the latter reported studies have implicated various G protein α subunits in mediating TP activation [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] and the latter studies [33, 60] indicate that the TP isoforms may indeed differentially couple to G s , G i and G h , these studies had not assessed possible differential coupling of TPα and TPβ to G q or G 12 family members. Thus, we investigated the specificity of TP signalling focussing on members of the G q and G 12 families [61] . Moreover, we investigated the requirement of a C-tail per se in mediating TP: G protein coupling and effector activation [61] . In similar studies investigating TP coupling to G 12 family members, both TPα and TPβ exhibited efficient U46619-induced Ca 2+ mobilization in cells co-transfected with Gα 12 but not in cells co-transfected with the vector pCMV5, serving as a control [61; Figure 2B ]. However, unlike that previously observed with G q members, neither TPα nor TPβ exhibited U46619induced rises in IP 3 generation in cells co-transfected with Gα 12 . These data indicated that G 12 subfamily members did not mediate TP activation of PLCβ isozymes and therefore that the source of Ca 2+ mobilization in the presence of G 12 members was not from IP 3 -operated intracellular [Ca 2+ ] i stores [61] . In follow up studies, [8-(N,N-diethylamino)-octyl-3,4,5trimethoxybenzoate, hydrochloride] (TMB-8), an antagonist of IP 3 -operated [Ca 2+ ] i stores, had no effect on Ca 2+ mobilization by either TP isoform in the presence of G 12 [61] . Furthermore, Verapamil, an inhibitor of voltage sensitive L-type Ca 2+ channels, reduced Gα 12 mediated Ca 2+ mobilization by TPα and TPβ indicating that the TP isoforms may mediate opening of L-type channels in a Gα 12 dependent signalling mechanism [61] . Taken together, these studies investigating the signalling by the TP isoforms indicate that both TPα and TPβ couple to both the G q and G 12 family with no apparent isoform specific differences in their signalling behaviour.
To further investigate the role of the C-tail per se in signalling by the TP receptors, we established a stable cell line over-expressing TP ∆328 , a deletion mutant of TPα and TPβ devoid of their divergent residues and, therefore, contains only those residues common to both TP isoforms.
Consistent with the lack of involvement of the C-tail in influencing ligand binding, TP ∆328 exhibited identical radioligand binding to that of the wild type TP receptors [61] . However, in the absence of a co-transfected G protein, TP ∆328 signalled more efficiently and mediated significantly greater U46619-induced [Ca 2+ ] i mobilization than did either the wild type TPα or TPβ receptors [61; Figure 2C ]. However, unlike that previously observed for the wild type TP receptors, TP ∆328 exhibited an impaired ability to couple to co-transfected G q or G 12 members as co-expression of either Gα 11 , Gα 16 or Gα 12 did not augment U46619-induced [Ca 2+ ] i mobilization by TP ∆328 [61; Figure 2D ]. Based on these observations, it appears that the C-tail region of the TP receptors does not act as a major determinant of G protein coupling specificity to members of the G q or G 12 families but may, however, act as a determinant of G protein coupling efficiency.
In view of the fact that TP isoforms were reported to oppositely regulate adenylyl cyclase activity [33] , we extended our studies to investigate whether TP ∆328 coupled to Gα s or Gα i to activate or inhibit adenylyl cyclase, respectively. Moreover, we investigated the effect of coexpression of Gα s or Gα i on U46619-induced second messenger generation by TP ∆328 . Similar to the TPα isoform, TP ∆328 mediated activation of adenylyl cyclase to bring about increases in cAMP generation but, unlike TPβ, it failed to couple to Gα i . However, in the absence of cotransfection of Gα s , cAMP generation by TP ∆328 was significantly greater than that of the wild-type TPα. Over-expression of Gα S , significantly augmented cAMP generation by TPα but had no effect on cAMP generation by TP ∆328 in response to U46619 [61] . Taken together, these data indicate that whilst the C-tail per se may not determine G-protein specificity to members of G q or G 12 family, it may play a role in determining G s versus G i coupling and it may be necessary for controlled, efficient G protein coupling and intracellular signalling, acting as a determinant of G protein coupling efficiency.
Isoprostanes and TP receptor activation:
In addition to the prostanoids, arachidonic acid may also be metabolised by free radical induced mechanisms to generate a novel class of lipid mediators referred to as the isoprostanes (iPs). The isoprostanes were originally discovered in 1990 by Morrow et al., [64] and are now believed to act as potent mediators of oxidative injury [64] [65] [66] [67] [68] . As such, the isoprostanes are mainly generated from arachidonic acid non-enzymatically and are synthesised in situ in phospholipids and then released through the actions of phospholipases, such as phospholipase A 2 [64, 65] . A wide range of prostanoid-like isoprostanes is generated including the PGF 2α -, the PGD 2 -, and PGE 2 -series [64, 69] . The F 2 series are the most common and one of these compounds 8-epi PGF 2α , also recently termed iPF 2α -III [69] , is the most abundant isoprostane generated in situations of oxidative injury [64] [65] [66] [67] [68] [69] . More recently, similar free-radical derived isomers of other polyunsaturated fatty acids have been described [69, 70] . Generation of 8-epi PGF 2α can be readily demonstrated experimentally in animal models of free radical injury, such as following administration of diaquat or carbon tetrachloride (CCl 4 ) where it is generated in abundance in a COX independent manner [64, 65] . Moreover, circulating isoprostane levels are elevated in several disease states involving oxidative stress, including atherosclerosis, chronic pulmonary disease, Alzheimer's disease and diabetes mellitus [69, 71] .
Among its biologic actions, 8-epi PGF 2α is a potent vascular and renal vasocostrictor and is a potent stimulator of vascular smooth muscle (VSM) mitogenesis. In platelets, it induces shape change (1 -10 µM) and at higher concentrations (100 µM), it induces reversible, but not irreversible, aggregation [65] and may augment the actions of weaker platelet agonists, such as collagen, ADP and arachidonic acid. Most surprisingly, it was found that many of the actions of 8-epi PGF 2α were blocked by the highly selective TP antagonist SQ29,548 [65, 72] leading to the suggestion that this isoprostane may act as an alternative ligand for TP(s) other than TXA 2 itself.
However, it was also suggested that 8-epi PGF 2α may have partial agonist activity mediated through the platelet TPs [73] . Moreover, it was also suggested that in VSM, 8-epi PGF 2α may act at receptor sites related to but distinct from TPs [74, 75] . Thus, in view of the controversy surrounding the actions of 8-epi PGF 2α , we sought to address whether the TP receptors indeed mediate the actions of 8-epi PGF 2α in human platelets and in mammalian cell lines that overexpress the human TP isoforms.
In human (h.) platelets, both the TXA 2 [71] . Thus, through our studies, we conclude that 8-epi PGF 2α represents an alternative ligand for TP activation and therefore, it is likely that incidental activation of the TP receptors by 8-epi PGF 2α may indeed contribute to and exacerbate the pathology associated with oxidative injury. In keeping with these data, Audoly et al., [87] recently reported that transgenic mice over-expressing the TPβ isoform in the vasculature, but not in platelets, exhibited an exaggerated pressor response to infused 8-epi PGF 2α (iPF 2α -III) compared to wild type mice, an effect that was blocked by the selective TP antagonist SQ29,548. Moreover, in TP knockout mice, both pressor responses to 8-epi PGF 2α and its effect on platelet function were abolished [87] .
TP receptor desensitization:
A commonly observed phenomenon among GPCRs is desensitization [26] . GPCRs can be subject to either homologous [88, 89] or heterologous desensitization [89] [90] [91] [92] [93] [94] , largely mediated via phosphorylation by the G-protein coupled receptor kinases (GRKs) or the second messenger regulated protein kinases (PKs), including cAMP dependent PKA and PKC [26, 95] . Such desensitizations provide mechanisms for feedback regulatory loops following receptor activation and also for cross talk between different second messenger systems [90] . Differences in the complement of Ser and Thr residues in their unique C-tail domains imply that the TPα and TPβ isoforms may be subject to differential homologous / heterologous desensitization [20, 32] . Both TPα and TPβ have recently been established to undergo agonist-induced homologous desensitization and phosphorylation in transfected HEK 293 cells [96] . In addition, recent studies indicate that TPβ, but not TPα, may undergo agonist-induced internalization [97, 98] and we have established that the TP isoforms are subject to differential prostanoid EP 1 receptor-induced desensitization mediated at PKC sites unique to the individual TPs [63] .
Intermolecular cross talk and / or heterologous desensitization have been widely documented to occur between the anti-aggregatory IP/ adenylyl cyclase system and the proaggregatory TP/ phospholipase C system within platelets and vascular smooth muscle [99] [100] [101] .
The counter regulatory roles of TXA 2 and PGI 2 may be illustrated experimentally if one examines the effect of PGI 2 on TXA 2 /U46619-induced platelet aggregation and signalling [62] whereby pre-exposure of platelets to PGI 2 or its mimetic cicaprost completely inhibits platelet aggregation and [Ca 2+ ] i mobilization in response to their secondary stimulation with the TP agonist U46619 [62; Figure 4A & 4B] . The main inhibitory actions of PGI 2 / adenylyl cyclase within platelets are believed to be mediated through its activation of cAMP-dependent PKA [101] . Many of the molecular targets of PGI 2 / PKA mediated inhibition of platelet aggregation have been identified and include PLC, thrombolamban, myosin light chain kinase and Gα 13 [62, [99] [100] [101] . However, in view of the essential role of PGI 2 and its receptor in modulating or counter regulating TXA 2 mediated signalling in platelets and VSM, we sought to investigate whether the TP receptors themselves may be direct targets in this desensitization process. Additionally, in view of the existence of 2 receptors for TXA 2 in humans, namely the TPα and TPβ isoforms, we sought to investigate whether the TP isoforms themselves may be subject to differential regulation or desensitization by PGI 2 mediated signalling. predicted to be the target residue for phosphorylation [62] . Site directed mutagenesis was employed to convert Ser 329 to Ala 329 , to generate TPα S329A . Initial characterisation of TPα S329A established that it displayed identical pharmacological properties, in terms of ligand binding and agonist mediated signalling, as the wild type TPα [62] . In HEK.TPα S329A cells, mammalian HEK293 cells which stably over-express TPα S329A , the TP agonist U46619 mediated efficient mobilization of [Ca 2+ ] i and IP 3 generation in a G q dependent manner [62] . However, unlike that which occurred in platelets or in HEK.TPα10 cells, pre-incubation of HEK.TPα S329A cells with cicaprost had no effect on TPα S329A mediated mobilization of [Ca 2+ ] i in response to secondary stimulation of cells with U46619 [62; Figure 5D ]. Subsequent, whole cell phosphorylation assays confirmed that TPα, but not TPβ or TPα S329A , is indeed a direct target of cicaprost / IPmediated PKA phosphorylation [62] . Thus, these studies confirm that TPα, but not TPβ, is subject to counter regulation or heterologous desensitization by IP, mediated through direct PKA phosphorylation within the unique C-tail of TPα whereby Ser 329 has been identified as the target residue for phosphorylation. An important implication of these studies is that TPα, but not TPβ, may be the TP isoform physiologically relevant to TP:IP mediated vascular hemostasis and implies that TPβ may have a redundant role in prostanoid-regulated vascular hemostasis.
Consistent with this hypothesis, based on observations that TP isoform specific antibodies permitted detection of TPα, but not TPβ in human platelets, Habib et al., [39] have proposed that TPα may be the predominant isoform in platelets, despite the presence of mRNA for both isoforms [33] .
In follow up studies, we have recently confirmed that the TP isoforms are also subject to this type of differential counter regulation of signalling by another inhibitory prostanoid, namely PGD 2 , thereby adding further credence to the hypothesis that the TP isoforms indeed play essential, though differential, roles in prostanoid regulated vascular hemostasis [102] . Within the vasculature, platelet derived PGD 2 inhibits platelet aggregation and causes relaxation of vascular smooth muscle leading to vasodilation [103, 104] . However, PGD 2 is also synthesised within the central nervous system, where is acts as a potent regulator of sleep induction, and also acts as a mediator of nociception (pain perception) and neurotransmitter release [1, 105, 106] . These actions of PGD 2 are mediated through a single PGD 2 receptor, termed DP, which is widely expressed in platelets, VSM, through out regions of the CNS, such as within the leptomeninges but not in the brain itself, and also within the retina and small intestinal tissue [1, 6] . Our finding that the TP isoforms are subject to differential desensitization or counter regulation of signalling by PGD 2 [102] , may also point to additional distinct roles of the TP isoforms not only within the vasculature but also in the CNS, where TPs are also abundantly expressed [1] .
Concluding remarks:
Our studies investigating the counter regulation of TP responses by PGI 2 / cicaprost and PGD 2 have established that the TPα, but not the TPβ isoform, is subject to IP-and DP-induced heterologous desensitization mediated through direct PKA phosphorylation of Ser 329 within the unique C-tail of TPα. These findings point to potentially important physiologic differences between the TP isoforms and imply that TPα may be the TP isoform involved in prostanoidregulated vascular hemostasis. In addition, these findings also imply that signalling by the TPβ isoform remains active or unchecked in response to the prostanoids PGI 2 and PGD 2 . Such lack of desensitization of TPβ signalling by the inhibitory prostanoids may have important physiological and / or clinical implications that are currently unappreciated. It is particularly noteworthy that it is the very first divergent amino acid residue between the TP isoforms, namely Ser 329 of TPα, that is the target for phosphorylation by PKA and, hence, the key mediator of regulation by the inhibitory prostanoids PG1 2 and PGD 2 . Whether this is a simple coincidence or a distinct incident of nature will remain an open, unresolved question.
In summary, in this review I have outlined some of our recent studies investigating TP expression and signalling, particularly as pertaining to the human TPα and TPβ isoforms. Our studies investigating the expression, tissue distribution and regulation of the TPα and TPβ isoforms have confirmed that they are subject to differential expression. Whereas the TP isoforms exhibit identical coupling to G q and G 12 family members, their unique C-tail sequences may play a role in determining G s versus G i coupling and may act as a determinant of receptor:G protein coupling efficiency. Our studies have provided convincing evidence that the TP isoforms mediate the actions, at least in part, of the free-radical derived isoprostane 8-epi PGF 2α leading to activation of TP signalling and TP mediated mitogenesis in VSM. Finally, our studies investigating the counter regulation of TP signalling by PGI 2 , have indeed confirmed that the TP receptor itself is a direct target for IP/PKA mediated desensitisation; however, the TP isoforms display distinct patterns of regulation, pointing to essentially differential roles for TPα and TPβ in the fundamental physiologic process of vascular hemostasis.
FIGURES:
TPβ β β β 
